A randomized, pilot trial of etanercept in dermatomyositis

• Published in: Annals of neurology Vol. 70; no. 3; pp. 427 - 436
• Main Authors: AMATO, Anthony A, TAWIL, Rabi, DILEK, Nuran, MARTENS, William B, EASTWOOD, Eileen, KISSEL, John, BAROHN, Richard, MCDERMOTT, Michael P, PANDYA, Shree, KING, Wendy, JANCIURAS, Joanne
• Format: Journal Article
• Language: English
• Published: Hoboken Wiley Subscription Services, Inc., A Wiley Company 01.09.2011; Wiley-Liss; Wiley Subscription Services, Inc
• Subjects: Adolescent; Adult; Anti-Inflammatory Agents - administration & dosage; Anti-Inflammatory Agents - therapeutic use; Anti-Inflammatory Agents, Non-Steroidal - adverse effects; Anti-Inflammatory Agents, Non-Steroidal - therapeutic use; Biological and medical sciences; Dermatomyositis - drug therapy; Dose-Response Relationship, Drug; Double-Blind Method; Drug therapy; Etanercept; Failure; Female; Humans; Immunoglobulin G - adverse effects; Immunoglobulin G - therapeutic use; Isometric Contraction - physiology; Kaplan-Meier Estimate; Male; Medical sciences; Middle Aged; Multiple sclerosis and variants. Guillain barré syndrome and other inflammatory polyneuropathies. Leukoencephalitis; Muscle Strength; Neurologic Examination; Neurology; Pilot Projects; Prednisone - administration & dosage; Prednisone - therapeutic use; Receptors, Tumor Necrosis Factor - therapeutic use; Treatment Failure; Treatment Outcome; Young Adult; Immunopathology; Connective tissue disease; Skin disease; Striated muscle disease; Nervous system diseases; Etanercept; Systemic disease; Dermatomyositis; Autoimmune disease

Objective: The aims of this pilot study were to assess (1) the safety and tolerability of etanercept in dermatomyositis (DM); (2) the feasibility and safety of a forced prednisone taper; and (3) outcome measures, including those recommended by the International Myositis Assessment Clinical Study (IM...